Skip to content
To assure the broad adoption of cutting-edge preventative measures that can shield Americans in the future, vaccine policy has to be changed, according to […]
Why vaccine policy must keep up with the science Read More »
While research into long COVID-19 is offering clues to causes and potential targets for treatment, defeating this debilitating condition, which impacts millions, requires a
BIO’s online conference invites biotech to fight long COVID Read More »
Already, 2023 is looking like a dynamic year for biotech on the state level as state legislatures nationwide get ready to tackle a few
4 things for biotech to watch in the 2023 state legislatures Read More »
On Thursday, the Centers for Medicare & Medicaid Services (CMS) released its proposed timeline for penalizing drug makers whose prices rise faster than inflation.
CMS releases timeline for inflation rebate on drug price increases Read More »
Partisan divisions were on display at a joint hearing of the House Energy & Commerce Committee’s Health and Oversight & Investigations subcommittees, as Republicans
Administration officials return to Congress to discuss COVID-19 response Read More »
Eleven years after the first CRISPR patent was filed, we’re anticipating what could be the first approval of a gene therapy based on CRISPR:
‘How do you price a cure?’ and other questions about the CRISPR era Read More »
In his State of the Union speech last night, President Joe Biden hailed the end of the COVID-19 emergency while ignoring the contribution of
State of the Union: Biden’s remarks on drug price controls and biomedical innovation Read More »
The number of new pain drugs in the development pipeline has slowed to a trickle and investment in addiction drugs is low, challenges addressed
‘All hands on deck’ needed to address U.S. pain and addiction innovation Read More »
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
“I think we’re in a very exciting time in healthcare and biotech,” said Steven Ladd, Director of Business Development and Acquisitions at AbbVie. “It’s
China-U.S. biotech ventures are where collaboration meets competition Read More »
